[Vitamin K epoxide reductase: Fresh blood for oral anticoagulant therapies]

Rev Med Interne. 2006 Dec;27(12):979-82. doi: 10.1016/j.revmed.2006.09.004. Epub 2006 Oct 11.
[Article in French]

Abstract

Introduction: Vitamin K epoxide reductase complex subunit I (VKORC1) is a key enzyme in the vitamin K cycle, cofactor required for the activation of vitamin K-dependent clotting factors.

Exegesis: VKORC1 recycles vitamin K 2,3 epoxide back to active vitamin K hydroquinone, an important factor for the carboxylation step of clotting factors. VKORC1 is the target enzyme of inhibition by oral anticoagulants or anti-vitamin K (warfarin, acenocoumarol).

Conclusion: We show here the clinical consequences of genetic variations of VKORC1 during VKA therapy.

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Algorithms
  • Anticoagulants / pharmacology*
  • Drug Resistance / genetics
  • Humans
  • Mixed Function Oxygenases / genetics*
  • Mixed Function Oxygenases / metabolism
  • Mutation
  • Polymorphism, Genetic
  • Vitamin K / genetics
  • Vitamin K / metabolism*
  • Vitamin K Epoxide Reductases

Substances

  • Anticoagulants
  • Vitamin K
  • Mixed Function Oxygenases
  • VKORC1 protein, human
  • Vitamin K Epoxide Reductases